[The clinical pharmacology of beta-adrenoblockers].
Beta-adrenoblockers (BAB) are highly-effective pharmaceuticals used broadly in treatment of cardial diseases. Response to BABs is known to display interindividual variability; pre-treatment analysis of allelic gene variants responsible for BAB pharmacokinetics, allows dose correction according to the genetic features of an individual patient. Pharmacogenetics is a young science, but it has already proven its practical significance in term of individualization of pharmacotherapy, which in some cases makes it possible to increase the effectiveness of the pharmaceuticals and avoid undesirable effects.
Sychev
D A
DA
Ramenskaia
G V
GV
Ignat'ev
I V
IV
Smirnikhina
S A
SA
Kazakov
R E
RE
Kukes
V G
VG
D000319:Adrenergic beta-Antagonists / Q000493:pharmacokinetics*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D004247:DNA / Q000235:genetics; D005838:Genotype; D006331:Heart Diseases / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D006801:Humans; D010597:Pharmacogenetics / Q000379:methods*; D011110:Polymorphism, Genetic
D000319:Adrenergic beta-Antagonists; D004247:DNA; D019389:Cytochrome P-450 CYP2D6